title: Neurotrophin delivery using nanotechnology.
abstract: Deficits or overexpression of neurotrophins cause neurodegenerative diseases and psychiatric disorders. These proteins are required for the maintenance of the function, plasticity and survival of neurons in the central (CNS) and peripheral nervous systems. Significant efforts have been devoted to developing therapeutic delivery systems that enable control of neurotrophin dosage in the brain. Here, we suggest that nanoparticulate carriers favoring targeted delivery in specific brain areas and minimizing biodistribution to the systemic circulation should be developed toward clinical benefits of neuroregeneration. We also provide examples of improved targeted neurotrophin delivery to localized areas in the CNS.
authors.affiliation: CNRS UMR8612 Institut Galien Paris-Sud, 5 rue J.B. Clément, F-92296 Châtenay-Malabry cedex, France; University Paris Sud 11, Faculté de Pharmacie, LabEx LERMIT, Châtenay-Malabry, France. Electronic address: Angelina.Angelova@u-psud.fr.
authors.forename: Angelina
authors.initials: A
authors.lastname: Angelova
authors.forename: Borislav
authors.initials: B
authors.lastname: Angelov
authors.forename: Markus
authors.initials: M
authors.lastname: Drechsler
authors.forename: Sylviane
authors.initials: S
authors.lastname: Lesieur
mesh_terms: D000818:Animals; D001921:Brain / Q000378:metabolism / Q000503:physiopathology; D002490:Central Nervous System / Q000502:physiology / Q000503:physiopathology; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000503:physiopathology; D053758:Nanoparticles; D036103:Nanotechnology; D009414:Nerve Growth Factors / Q000008:administration & dosage* / Q000235:genetics; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000503:physiopathology; D014018:Tissue Distribution
chemical_list: D009414:Nerve Growth Factors